Related Experiment Videos
New vinca alkaloids and related compounds
1Department of Medicine, North Shore University Hospital-Cornell University Medical College, Manhasset, NY.
Seminars in Oncology
|December 1, 1992
Summary
Vinca alkaloids are useful anticancer drugs, but new derivatives like vinorelbine show promise for breast cancer. Ongoing trials will determine their full potential and safety in treating malignancies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Vinca alkaloids are established anticancer agents.
- Previous analogs have not significantly improved safety or efficacy.
- New derivatives are under clinical investigation.
Purpose of the Study:
- To review the current status of novel vinca alkaloid derivatives in cancer treatment.
- To highlight the clinical progress of vinorelbine, vintripol, and vinxaltine.
- To discuss the potential role of rhizoxin as a similar anticancer agent.
Main Methods:
- Review of ongoing clinical trials for vinca alkaloid derivatives.
- Analysis of preliminary efficacy and toxicity data.
- Comparison with existing and novel anticancer agents.
Main Results:
- Vinorelbine demonstrates consistent antitumor activity in breast carcinoma and is in Phase III trials.
- Vintripol and vinxaltine are in early clinical trials, with leukopenia as a dose-limiting toxicity.
- Rhizoxin shows initial activity in breast carcinoma and is in Phase II trials.
Conclusions:
- Novel vinca alkaloid derivatives show promise in cancer therapy, particularly for breast carcinoma.
- Further clinical studies are required to establish the definitive role of these agents.
- Leukopenia remains a key toxicity to manage for these anticancer agents.